LIT-Leibniz-Institute for Immunotherapy
Business Strategies
The Leibniz Institute for Immunotherapy (LIT), an institute of the Leibniz Association, was created in 2022 from the RCI Regensburg Center for Interventional Immunology. The LIT's mission is to develop innovative cell therapies to treat cancer, autoimmune diseases and chronic inflammation. Using synthetic and pharmacological strategies, we reprogram immune cells to save lives.
Core Technologies and Services
Research in the fields:
- Suppression of rejection reactions after organ and stem cell transplants while maintaining the immune system's ability to fight pathogens and cancer cells.
- Improved treatment of rheumatism and chronic inflammatory bowel diseases through targeted interventions in the immune system.
- Use of the immune system to fight cancer cells so that chemotherapy and radiation need to be used less aggressively in the future.
Patent, Licenses, Co-operations
The LIT's close collaboration with the university hospital, companies (including BioPark Regensburg) and the universities of Regensburg, Erlangen-Nuremberg and Würzburg (Immune Medicine Research Alliance) enables synergy effects so that modern therapies can be made available to patients at an early stage. The LIT also has a GMP facility in which the production of cell based medicines for individual immunotherapies is possible.
